This class of drugs is commonly called GLP-1 agonists, which stands for glucagon-like peptide 1
By addressing these risk factors, Semaglutide offers a protective effect for patients, particularly those with Type 2 diabetes or obesity
Patients should not use a compounded drug if an approved drug is available to treat a patient
Medical evaluation is appropriate if symptoms: Are severe, persistent, or worsening Are accompanied by vomiting or dehydration Cause significant abdominal pain Interfere with nutrition or daily function Do not improve despite diet and portion adjustments Occur with new or concerning gastrointestinal symptoms Bottom line sulfur burps and bloating on GLP-1 medications Sulfur burps and bloating on GLP-1 medications are common digestive side effects driven by delayed gastric emptying , not abnormal digestion
You may still be a candidate for the Fitish Microdosing program, a lower dose option for patients who want a gentler, cosmetic approach
Other medications may interfere with hormone levels and create confusion during testing
